Safety, Tolerability, and Efficacy of TAR-200 in Patients with Muscle-Invasive Bladder Cancer Who Refused or Were Unfit for Curative-Intent Therapy: A Phase 1 study

Authors

Mark D. Tyson
David Morris
Juan Palou
Marie Carmen Mir
Rian J. Dickstein
Felix Guerrero-Ramos
Jason M. Hafron, Beaumont Health

Document Type

Conference Proceeding

Publication Date

11-2-2022

Recommended Citation

Tyson MD, Morris D, Palou J, Mir MC, Dickstein RJ, Guerrero-Ramos F et al. [Hafron JM] Safety, tolerability, and efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a Phase 1 study. Presentation at: Western Section American Urological Association (AUA)Meeting; 2022 Oct 30-Nov 4; Kauai HI.

Comments

Western Section American Urological Association (AUA) Meeting ; Oct 30- Nov 4, 2022 ;Kauai HI.